An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort

Rheumatology (Oxford). 2015 Apr;54(4):623-32. doi: 10.1093/rheumatology/keu375. Epub 2014 Sep 17.

Abstract

Objective: The aim of this study was to develop an SLE disease model that simulates long-term outcomes of SLE to estimate the long-term effectiveness and cost-effectiveness of SLE treatments.

Methods: Longitudinal data from 1354 patients from the Hopkins Lupus Cohort were included in the analysis. Statistical models were created to estimate disease activity [Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA) SLEDAI scale] and prednisone dose over time using linear regression. Survival models for organ damage and mortality were created. The models were combined in a predictive simulation of SLE organ damage and mortality. Predictions were assessed against the Hopkins Lupus Cohort data.

Results: The analyses found that change in the annual average SLEDAI score was associated with the previous annual average SLEDAI score, renal involvement, age, male gender, African American ethnicity, anaemia, haematological involvement, increased DNA binding and low complement. The annual average prednisone dose increased for every unit increase in annual average SLEDAI. Organ damage and mortality modelling demonstrated that adjusted mean SLEDAI and binary SLEDAI organ involvement indicators predicted mortality, cardiovascular, renal, neuropsychiatric, pulmonary, gastrointestinal, ocular and skin damage. The cumulative average prednisone dose was associated with risk of cardiovascular, ocular, musculoskeletal, neuropsychiatric and gastrointestinal damage, gonadal failure and diabetes mellitus. The simulation reproduced mean SLEDAI and organ damage scores from the Hopkins Lupus Cohort.

Conclusion: Longitudinal modelling of an SLE cohort confirmed relationships between risk factors and long-term outcomes in SLE. The models serve to estimate the probability of SLE outcomes over time and can be used to estimate the effectiveness and cost-effectiveness of new treatments.

Keywords: epidemiology; health economics; health outcomes; statistics; systemic lupus erythematosus.

MeSH terms

  • Adult
  • African Americans
  • Anemia / etiology
  • Anemia / therapy*
  • Cohort Studies
  • Cost-Benefit Analysis
  • European Continental Ancestry Group
  • Female
  • Health Care Costs*
  • Humans
  • Immunosuppressive Agents / economics
  • Immunosuppressive Agents / therapeutic use*
  • Linear Models
  • Longitudinal Studies
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / mortality
  • Lupus Nephritis / etiology
  • Lupus Nephritis / therapy*
  • Male
  • Middle Aged
  • Models, Statistical
  • Outcome Assessment, Health Care
  • Prednisone / economics
  • Prednisone / therapeutic use*
  • Prospective Studies
  • Severity of Illness Index
  • Sex Factors
  • Survival Analysis

Substances

  • Immunosuppressive Agents
  • Prednisone